Osimertinib

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.

Today is World Lung Cancer Day.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more.

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more.

An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.

The FDA approved osimertinib plus platinum-based chemotherapy for certain adults with locally advanced or metastatic non-small cell lung cancer.